Richard Carvajal on Multidisciplinary Approach to Managing Immunotherapy Toxicities

Video

Richard Carvajal, MD, discusses the importance of a multidisciplinary approach when monitoring patients for immunotherapy toxicities.

Richard Carvajal, MD, Columbia University Medical Center, discusses the importance of a multidisciplinary approach when monitoring patients for immunotherapy toxicities.

Nursing staff are vital when it comes to follow-up with patients on immunotherapy treatments. Daily phone calls may even be necessary to ensure that patients are monitored as needed. For combination immunotherapy treatments, Carvajal suggests using the wisdom seen in the single agents. Staff must be hypervigilant and there must be standards developed for follow-up and management of these patients.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Related Content
Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

The Vitals Podcast

Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Lindsay Fischer
May 19th 2023
Podcast

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Illustration of a clipboard with the word "Guidelines" on top of the page, followed by a check list

NCCN Guideline Updates on ctDNA Stance in MCC and Colon, Rectal Cancer

Kyle Doherty
February 22nd 2025
Article

The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.

the vitals

Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

Lindsay Fischer
May 4th 2023
Podcast

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Image of FDA on a clipboard.

Cosibelimab Approved by FDA for Metastatic, Locally Advanced Cutaneous Squamous Cell Carcinoma

Kristi Rosa
December 13th 2024
Article

An FDA approval was granted for cosibelimab-ipdl for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

FDA on clipboard

Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma

Ashling Wahner
November 24th 2024
Article

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated melanoma.